INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE
ORDER A TEST Log In Contact Us
image description
CARE PATHWAY intelligence SOLUTIONs

Tempus Next Oncology

An AI-enabled care pathway platform that enables oncology providers to deliver the Next step in a patient’s care journey.

schedule a demo LOG IN

Improve adherence to clinical guidelines through AI-enabled and targeted notifications at the point of care.

image description image description

Our Solution

Tempus Next: AI-enabled care pathway intelligence

Tempus Next applies technology, data, and AI to enable precision medicine, empowering providers to deliver the next step in a cancer patient’s care journey and foster value based care within health systems.

Identify and contextualize cancer patients in their care journey

AI-enabled solutions designed to surface deep insights from multimodal, longitudinal patient data including medical imaging data, EHR data, lab results, pathology reports and clinician notes.

image description

Surface precision care pathways at the point of care

Tiered and customized notifications consistent with precision medicine guidelines in the physician’s workflow reduce alert fatigue.

image description

Track patients for timely follow-up to help improve outcomes

Patient Tracking for patients with current disease who need management, Patient Lists to search for subsets of patients and Dashboards to track insights into a hospital’s patient population.

image description

Monitor notification effectiveness and guidelines adoption

Institution-level insights reports delivered to hospital systems help understand effectiveness of the notifications, emerging trends in guideline adoption, and patient outcomes.

image description

Increase equitable access to care

Timely and accurate diagnostics, procedures and therapies for all cancer patients, regardless of socioeconomic status.

Figure: In this study, black patients saw a larger decrease in average time from index echo to follow up (120 vs 64 days) compared to white patients (57 to 36 days), showing the improvement in black patients’ time to follow up towards the average seen in white patients’ (narrowing the gap).

Horde G, Sotelo M, D’Amico A, et al. Use of an echocardiographic-based, artificial intelligence system to improve racial disparities in care of patients with valvular heart disease. European Heart Journal – Cardiovascular Imaging. 2023;24(Suppl 1):38.3.

image description

Using AI to Identify and Close Gaps in Care for Cancer Patients

Learn how TriHealth Cancer and Blood Institute implemented Tempus Next to accelerate the adoption of precision care pathways for NSCLC patients.

Watch our webinar

Case Study

Closing the biomarker testing gap for early stage NSCLC (Non-small cell lung cancer) patients with Tempus Next

Learn how Tempus Next was deployed at TriHealth Cancer and Blood Institute in Cincinnati, Ohio to surface and close gaps in biomarker testing for NSCLC patients.

LEARN MORE
image description

Tempus Next for Oncology

  • Reduce undertesting of biomarkers associated with immunotherapy eligibility  (PDL1, MSI, TMB)

  • Identify patients with actionable alterations to consider for FDA approved targeted therapies consistent with clinical guidelines

  • Help prevent chemotherapy toxicity in patients with identifiable pharmacogenomic alterations

Learn more about Tempus Next

Chris Scotto DiVetta, SVP of Applications at Tempus AI introduces Tempus Next, an AI enabled care pathway platform that helps providers accelerate the adoption of evidence based care.

Watch replay

This is data-driven precision medicine

This is the future of healthcare.